Pmu152 Switching Among Biologic Therapies in Patients With Rheumatoid Arthritis: A Cross-Sectional Study

Abstract

Conclusions: This study demonstrate that biosimilar drug market increased during the period. The "Health National Strategy » biosimilar objective for 2022: 80% of market share is achievable if the market keeps the actual trend. Patient's characteristics description could be complementary to this study, to give more information to the biosimilar landscape.